^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CLDN18.2-targeted antibody-drug conjugate

    Related drugs:
    1d
    A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=151, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P2 trial
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    garetatug rezetecan (SHR-A1904)
    10d
    Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 (clinicaltrials.gov)
    P3, N=2130, Recruiting, AstraZeneca
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • CLDN18.2 expression • PD-L1 negative • CLDN18.2 positive • CLDN1 positive
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab-clzb) • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)
    17d
    IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Zhejiang University
    New P2 trial
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    capecitabine • albumin-bound paclitaxel • arcotatug tavatecan (TAK-921)
    17d
    D9804C00001: Master protocol of novel agents or combinations as perioperative treatment in participants nwith locally advanced resectable gastroesophageal adenocarcinoma. (2024-516909-23-00)
    P1/2, N=17, Recruiting, AstraZeneca AB
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 positive • HER-2 negative • CLDN18.2 positive • CLDN18.2 positive + HER-2 negative
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)
    17d
    D8930C00001: A trial to learn how safe AZD4360 is, how well it works, and how it moves throughout the body over time in adults with advanced solid tumors (2024-518281-27-00)
    P1/2, N=17, Recruiting, AstraZeneca AB
    New P1/2 trial
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN18.2 positive • CLDN1 positive
    23d
    CLARITY-PanTumor01: AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 (clinicaltrials.gov)
    P2, N=224, Recruiting, AstraZeneca | Trial completion date: Dec 2026 --> Sep 2027 | Trial primary completion date: Dec 2025 --> Aug 2026
    Trial completion date • Trial primary completion date • Pan tumor
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    gemcitabine • 5-fluorouracil • leucovorin calcium • sonesitatug vedotin (AZD0901) • Onivyde (nanoliposomal irinotecan)
    29d
    LM302-03-101: LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. (clinicaltrials.gov)
    P3, N=387, Active, not recruiting, LaNova Medicines Zhejiang Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 negative • CLDN18.2 positive
    |
    AiTan (rivoceranib) • irinotecan • tecotabart vedotin (LM-302)
    1m
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. (clinicaltrials.gov)
    P3, N=752, Not yet recruiting, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    HER-2 negative • HER-2 expression • CLDN18.2 positive • CLDN1 positive
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • tecotabart vedotin (LM-302)
    1m
    JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma. (clinicaltrials.gov)
    P3, N=560, Recruiting, Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 negative
    |
    paclitaxel • docetaxel • irinotecan
    2ms
    First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer (clinicaltrials.gov)
    P1, N=163, Active, not recruiting, TORL Biotherapeutics, LLC | Recruiting --> Active, not recruiting | N=70 --> 163 | Trial primary completion date: Feb 2026 --> Jun 2026
    Enrollment closed • Enrollment change • Trial primary completion date • First-in-human
    2ms
    CLINCH-2: Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=132, Not yet recruiting, Antengene Biologics Limited
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 negative • PD-L1 negative
    |
    Keytruda (pembrolizumab) • capecitabine • oxaliplatin • ATG-022
    2ms
    A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients (clinicaltrials.gov)
    P1, N=156, Recruiting, Shanghai Institute Of Biological Products | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive